Randomized trial · people

Semaglutide (oral): heart risk not higher than placebo in PIONEER 6

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes at high heart risk, oral semaglutide met the trial's test for not adding heart risk compared with placebo. More people on it stopped treatment because of stomach and gut side effects.

Kind
Randomized trial
Studied in
People
Number studied
3183
Published
2019
Journal
N Engl J Med

What they tested

The team tested whether once-daily oral semaglutide raises the risk of major heart events in people with type 2 diabetes compared with placebo, a dummy pill.

How the study was done

A randomized, double-blind, placebo-controlled trial in 3183 people with type 2 diabetes at high heart risk. They were age 50 or older with heart or chronic kidney disease, or age 60 or older with heart risk factors only. People were followed for a median of 15.9 months, and the trial was set up to rule out a heart risk 80% higher than with placebo.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Major heart events occurred in 61 of 1591 people (3.8%) on oral semaglutide and 76 of 1592 (4.8%) on placebo. These events were heart-related death, a nonfatal heart attack or a nonfatal stroke. The hazard ratio, a measure of relative risk over time, was 0.79 (95% CI 0.57 to 1.11), which met the trial's goal of showing no excess risk (P<0.001). Heart-related death occurred in 0.9% vs 1.9% (hazard ratio 0.49), death from any cause in 1.4% vs 2.8% (hazard ratio 0.51), nonfatal heart attacks in 2.3% vs 1.9%, and nonfatal strokes in 0.8% vs 1.0%. Stomach and gut side effects that led people to stop treatment were more common with oral semaglutide.

What it doesn’t show

The trial was built to rule out added heart risk, not to prove a reduction, and its median follow-up was 15.9 months. It was funded by Novo Nordisk.

The paper

Husain et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019.

The compounds

More studies on Semaglutide (oral)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo